Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Riliprubart, a second-generation humanized immunoglobulin G4 that inhibits only the activated form of the C1s component of the proximal classical complement pathway, is currently in clinical development for complement-mediated diseases. WHAT QUESTION DID THIS STUDY ADDRESS? Model-informed drug development (MIDD) approaches were used to propose a dose regimen utilizing available clinical data.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
